Sympathetic Nervous System in Heart Failure: Targets for Treatments.

Area of Science:

• Cardiology
• Neurology
• Autonomic Nervous System Research

Background:

• Heart failure (HF) involves autonomic nervous system (ANS) imbalance, specifically chronic sympathetic nervous system (SNS) overactivity.
• This overactivity contributes to maladaptive cardiac remodeling, arrhythmias, and hemodynamic instability in HF patients.

Purpose of the Study:

• To review current and emerging neuromodulatory therapies for HF.
• To discuss the future development of novel therapies targeting ANS dysfunction in HF.

Main Methods:

• Review of existing literature on neuromodulatory interventions for HF.
• Analysis of emerging therapies including gene therapy and endovascular baroreflex activation therapy (BAT).

Main Results:

• Neuromodulatory therapies (SNM, VNS, BAT, RDN) reduce sympathetic output, improving cardiac function and hemodynamics in HF.
• Current implementation is limited by response variability, patient selection challenges, and insufficient long-term data.
• Emerging gene therapies and endovascular BAT show potential for reducing sympathetic overactivation and improving HF symptoms and function.

Conclusions:

• Neuromodulation is a key strategy for managing HF driven by autonomic dysfunction.
• Long-term impact on HF progression and survival requires further demonstration.
• Future research must focus on deep phenotyping for patient selection, comparative trials, and large-scale studies to optimize procedures and assess long-term efficacy.